GATESHEAD HEALTH NHS FOUNDATION TRUST

EMA's CHMP recommended Gilead Sciences' seladelpar for EU approval as a second-line PBC treatment, either with UDCA or alone for non-UDCA responders/intolerants. The European Commission is expected to decide by early 2025. Seladelpar, already U.S.-approved as Livdelzi, targets PPAR-delta to manage liver inflammation and symptoms like itching, based on Phase 3 RESPONSE trial data showing significant improvement in liver damage markers and itch relief. An ongoing Phase 3 AFFIRM trial tests its efficacy in PBC patients with compensated cirrhosis.

DaRe2THINK, led by Professor Dipak Kotecha, aims to improve health by screening over 13 million NHS patients' records to prevent strokes, blood clots, and vascular dementia in atrial fibrillation patients. The project requires inviting only 5.3 patients for one to be randomized, surpassing other trials. Supported by a Patient & Public Engagement team, it transforms NHS trial conduct, enhancing participation and contributing to the UK's life science strategy.

P.E.I. hired 37 physicians in the past year, including four associate physicians and one physician assistant, aiming to ease the health-care crunch. For the first time, associate physicians and physician assistants are joining the provincial system. A medical oncologist and an internal medicine physician will start at Queen Elizabeth Hospital in September 2025.

ACTICOR BIOTECH updates on LIBERATE (phase 2b) and GLORIA (phase 2) studies evaluating glenzocimab for myocardial infarction treatment, aiming for phase 3 registration by 2027.

A groundbreaking AI-powered risk prediction tool, P-CARDIAC, is set to revolutionize CVD prevention and management in the Chinese population, led by Professor Celine Chui Sze-ling at The University of Hong Kong. The HEARTWISE study will evaluate P-CARDIAC's effectiveness in secondary care, focusing on personalized risk assessment, risk thresholds, and pharmacist-led services. The study aims to reduce CVD burden in Hong Kong and beyond, with potential global impact.